首页 > 最新文献

Journal of Urology最新文献

英文 中文
Editorial Comment. 编辑评论。
IF 5.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-04-01 Epub Date: 2025-01-10 DOI: 10.1097/JU.0000000000004403
Srinath-Reddi Pingle, Andrew T Lenis
{"title":"Editorial Comment.","authors":"Srinath-Reddi Pingle, Andrew T Lenis","doi":"10.1097/JU.0000000000004403","DOIUrl":"10.1097/JU.0000000000004403","url":null,"abstract":"","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"445-446"},"PeriodicalIF":5.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply by Authors. 作者回复。
IF 5.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-04-01 Epub Date: 2025-01-13 DOI: 10.1097/JU.0000000000004412
Jacob E Tallman, Emily A Vertosick, Syed M Alam, Fady J Baky, S Machele Donat, Eugene J Pietzak, Eugene K Cha, Timothy F Donahue, Bernard H Bochner, Andrew J Vickers, Alvin C Goh
{"title":"Reply by Authors.","authors":"Jacob E Tallman, Emily A Vertosick, Syed M Alam, Fady J Baky, S Machele Donat, Eugene J Pietzak, Eugene K Cha, Timothy F Donahue, Bernard H Bochner, Andrew J Vickers, Alvin C Goh","doi":"10.1097/JU.0000000000004412","DOIUrl":"10.1097/JU.0000000000004412","url":null,"abstract":"","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"446"},"PeriodicalIF":5.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial Comment. 编辑评论。
IF 5.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-04-01 Epub Date: 2024-12-20 DOI: 10.1097/JU.0000000000004375
David Ostrowski, John K Weaver
{"title":"Editorial Comment.","authors":"David Ostrowski, John K Weaver","doi":"10.1097/JU.0000000000004375","DOIUrl":"10.1097/JU.0000000000004375","url":null,"abstract":"","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"492"},"PeriodicalIF":5.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urologic Oncology: Adrenal, Renal, Ureteral, and Retroperitoneal Tumors. 泌尿肿瘤:肾上腺、肾、输尿管及腹膜后肿瘤。
IF 5.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-04-01 Epub Date: 2024-12-24 DOI: 10.1097/JU.0000000000004364
M Pilar Laguna
{"title":"Urologic Oncology: Adrenal, Renal, Ureteral, and Retroperitoneal Tumors.","authors":"M Pilar Laguna","doi":"10.1097/JU.0000000000004364","DOIUrl":"10.1097/JU.0000000000004364","url":null,"abstract":"","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"534-536"},"PeriodicalIF":5.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial Comment.
IF 5.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-03-14 DOI: 10.1097/JU.0000000000004502
Margaret Meagher, Kshitij Pandit, Dhruv Puri, Mai Dabbas, Aditya Bagrodia
{"title":"Editorial Comment.","authors":"Margaret Meagher, Kshitij Pandit, Dhruv Puri, Mai Dabbas, Aditya Bagrodia","doi":"10.1097/JU.0000000000004502","DOIUrl":"https://doi.org/10.1097/JU.0000000000004502","url":null,"abstract":"","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"101097JU0000000000004502"},"PeriodicalIF":5.9,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial Comment.
IF 5.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-03-14 DOI: 10.1097/JU.0000000000004507
Richard S Matulewicz, Joel Sheinfeld
{"title":"Editorial Comment.","authors":"Richard S Matulewicz, Joel Sheinfeld","doi":"10.1097/JU.0000000000004507","DOIUrl":"https://doi.org/10.1097/JU.0000000000004507","url":null,"abstract":"","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"101097JU0000000000004507"},"PeriodicalIF":5.9,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply by Authors.
IF 5.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-03-14 DOI: 10.1097/JU.0000000000004510
Jiwei Huang
{"title":"Reply by Authors.","authors":"Jiwei Huang","doi":"10.1097/JU.0000000000004510","DOIUrl":"https://doi.org/10.1097/JU.0000000000004510","url":null,"abstract":"","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"101097JU0000000000004510"},"PeriodicalIF":5.9,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial Comment.
IF 5.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-03-14 DOI: 10.1097/JU.0000000000004503
Shomik Sengupta
{"title":"Editorial Comment.","authors":"Shomik Sengupta","doi":"10.1097/JU.0000000000004503","DOIUrl":"https://doi.org/10.1097/JU.0000000000004503","url":null,"abstract":"","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"101097JU0000000000004503"},"PeriodicalIF":5.9,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial Comment.
IF 5.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-03-13 DOI: 10.1097/JU.0000000000004489
Juan Chipollini
{"title":"Editorial Comment.","authors":"Juan Chipollini","doi":"10.1097/JU.0000000000004489","DOIUrl":"https://doi.org/10.1097/JU.0000000000004489","url":null,"abstract":"","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"101097JU0000000000004489"},"PeriodicalIF":5.9,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of Complication and Readmission Rates Between Robot-Assisted and Open Radical Cystectomy: Results From the Randomized RAZOR Clinical Trial.
IF 5.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-03-13 DOI: 10.1097/JU.0000000000004497
Vivek Venkatramani, Isildinha M Reis, Mark L Gonzalgo, Sanjaya Swain, Robert S Svatek, Dipen J Parekh

Purpose: To assess differences in complications and readmissions between robot-assisted radical cystectomy (RARC) and open radical cystectomy (ORC).

Materials and methods: This study uses data from the per-protocol population of the Randomized Robotic-Assisted vs Open Radical Cystectomy (RAZOR) study; a multicenter, open-label, phase-3, noninferiority clinical trial. RAZOR enrolled across 15 academic medical centers in the United States between 2011 and 2014. The median follow-up was 2 years. Complications up to 90 days using the Clavien-Dindo classification, and readmissions at 90 days and 1 year postoperatively were compared. Multivariable logistic regression analyses were performed to determine any predictors of major complications and of postsurgery readmission.

Results: Baseline characteristics were similar, and there was no significant difference in overall and major complication rates between RARC (n = 150) and ORC (n = 152) arms. Simplified frailty index (sFI) ≥ 3 (HR, 4.22, 95% CI, 2.67-6.66, P < .0001) was a significant predictor of major complications within 90 days. Readmission rates at 90 days were 24.1% for RARC and 23.1% for ORC, and readmission rates at at 1 year were 29.5% for RARC and 28.5% for ORC (P = .80). sFI ≥ 3 was a significant predictor of readmission at both time points (subdistribution HR [sHR] 4.43, 95% CI, 1.75-11.2, P = .002 at 90 days and sHR, 5.28, 95% CI, 2.22-12.6, P = <.001, at 1 year).

Conclusions: No significant differences in major complications and readmission rates between ORC and RARC were noted. Patient frailty was an important predictor of these outcomes, and special attention needs to be taken in ensuring appropriate patient selection and preoperative preparation.

Trial registration: ClinicalTrials.gov Identifier: NCT01157676.

{"title":"Comparison of Complication and Readmission Rates Between Robot-Assisted and Open Radical Cystectomy: Results From the Randomized RAZOR Clinical Trial.","authors":"Vivek Venkatramani, Isildinha M Reis, Mark L Gonzalgo, Sanjaya Swain, Robert S Svatek, Dipen J Parekh","doi":"10.1097/JU.0000000000004497","DOIUrl":"https://doi.org/10.1097/JU.0000000000004497","url":null,"abstract":"<p><strong>Purpose: </strong>To assess differences in complications and readmissions between robot-assisted radical cystectomy (RARC) and open radical cystectomy (ORC).</p><p><strong>Materials and methods: </strong>This study uses data from the per-protocol population of the Randomized Robotic-Assisted vs Open Radical Cystectomy (RAZOR) study; a multicenter, open-label, phase-3, noninferiority clinical trial. RAZOR enrolled across 15 academic medical centers in the United States between 2011 and 2014. The median follow-up was 2 years. Complications up to 90 days using the Clavien-Dindo classification, and readmissions at 90 days and 1 year postoperatively were compared. Multivariable logistic regression analyses were performed to determine any predictors of major complications and of postsurgery readmission.</p><p><strong>Results: </strong>Baseline characteristics were similar, and there was no significant difference in overall and major complication rates between RARC (n = 150) and ORC (n = 152) arms. Simplified frailty index (sFI) ≥ 3 (HR, 4.22, 95% CI, 2.67-6.66, <i>P</i> < .0001) was a significant predictor of major complications within 90 days. Readmission rates at 90 days were 24.1% for RARC and 23.1% for ORC, and readmission rates at at 1 year were 29.5% for RARC and 28.5% for ORC (<i>P</i> = .80). sFI ≥ 3 was a significant predictor of readmission at both time points (subdistribution HR [sHR] 4.43, 95% CI, 1.75-11.2, <i>P</i> = .002 at 90 days and sHR, 5.28, 95% CI, 2.22-12.6, <i>P</i> = <.001, at 1 year).</p><p><strong>Conclusions: </strong>No significant differences in major complications and readmission rates between ORC and RARC were noted. Patient frailty was an important predictor of these outcomes, and special attention needs to be taken in ensuring appropriate patient selection and preoperative preparation.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT01157676.</p>","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"101097JU0000000000004497"},"PeriodicalIF":5.9,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Urology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1